MedTrace Logo

Changes in Striatal [11C]ORM-13070 Binding Elicited by Changing Levels of Endogenous Noradrenaline

NCT01794975 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2013-02-20

No results posted yet for this study

Summary

The primary objective of the study is to further investigate whether striatal \[11C\]ORM-13070 uptake can be reduced by physiological and pharmacological challenges that increase the synaptic concentrations of noradrenaline in the human brain. Each subject will undergo 3 PET scans, a baseline PET scan and two scans with noradrenaline challenges: intravenous administration of ketamine and oral administration of atomoxetine combined with a cold pressor test where the subject's foot is placed in an 8 °C water basin. Eight healthy male subjects will be included in the study.

Conditions

  • Changes in Striatal [11C]ORM-13070 Binding.

Interventions

DRUG

Ketamine

DRUG

Atomoxetine

OTHER

Cold pressor test

DRUG

Placebo

Sponsors & Collaborators

  • Turku University Hospital

    collaborator OTHER_GOV

  • Orion Corporation, Orion Pharma

    collaborator INDUSTRY

  • University of Turku

    lead OTHER

Principal Investigators

  • Juha Rinne, PhD · Turku PET Centre

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01794975 on ClinicalTrials.gov